(:ONTX)

Apr 02, 2024 07:15 am ET
Traws Pharma Announces New Employee Inducement Grants
Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the...
Apr 02, 2024 07:00 am ET
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), and Trawsfynydd Therapeutics, Inc. (“Trawsfynydd”), a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID and other infectious...
Mar 08, 2024 08:00 am ET
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will present an...
Dec 12, 2023 08:00 am ET
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preclinical data, highlighting...
Dec 08, 2023 04:05 pm ET
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preclinical data highlighting...
Nov 28, 2023 08:00 am ET
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D.,...
Nov 14, 2023 04:05 pm ET
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results...
Nov 07, 2023 04:05 pm ET
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release...
Nov 02, 2023 10:37 am ET
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova and collaborators...
Oct 24, 2023 08:00 am ET
Onconova Expands Leadership Team with Two Key Appointments
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company expanded its...
Oct 19, 2023 08:00 am ET
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that one of the Company’s scientific...
Oct 12, 2023 08:00 am ET
Encouraging Rigosertib Data Presented at EADV as Late Breaker
(GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that a...
Sep 28, 2023 08:00 am ET
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that a late-breaking abstract...
Sep 06, 2023 08:00 am ET
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D.,...
Aug 10, 2023 04:05 pm ET
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported second quarter 2023 financial...
Aug 03, 2023 04:05 pm ET
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release...
Jun 14, 2023 08:00 am ET
Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today presented preclinical data on narazaciclib at...
Jun 05, 2023 08:00 am ET
Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the presentation of a Trials in Progress poster at...
May 25, 2023 08:00 am ET
Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blo
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first participant has been dosed in an...
May 15, 2023 04:18 pm ET
Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended March...
May 12, 2023 08:00 am ET
Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven M. Fruchtman, M.D.,...
May 11, 2023 08:00 am ET
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first patient has been dosed in the...
May 08, 2023 08:00 am ET
Onconova Therapeutics to Present at the ISID International Epidermolysis Bullosa Symposium
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced an upcoming presentation at the...
May 04, 2023 04:05 pm ET
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release...
Apr 19, 2023 09:00 am ET
Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced new preclinical data on...
Apr 06, 2023 04:05 pm ET
Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that its Chief Medical Officer...
Mar 23, 2023 08:00 am ET
Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, and Pangea Biomed, a company combining machine learning and deep RNA...
Mar 16, 2023 04:04 pm ET
Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the twelve months ended...
Mar 15, 2023 08:00 am ET
Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of two abstracts that have been...
Mar 09, 2023 04:05 pm ET
Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its fourth...
Mar 07, 2023 08:00 am ET
Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib’s Mechanisms of Action at the AACR Targeting RAS Conference
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced new preclinical data characterizing rigosertib’s...
Feb 07, 2023 08:00 am ET
Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma
Two of two evaluable participants in an ongoing investigator-sponsored program of rigosertib in RDEB-associated squamous cell carcinoma (SCC) have achieved a complete response of all cancerous skin lesions First evaluable participant has been in...
Feb 01, 2023 08:00 am ET
Onconova Therapeutics to Present at the 2023 Guggenheim Oncology Conference
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the 2023...
Jan 26, 2023 08:00 am ET
Onconova Therapeutics Announces Participation in the Channelchek Takeaway Series
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced their participation in the Channelchek Takeaway Series from the...
Dec 19, 2022 04:05 pm ET
Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the appointments of Peter Atadja, Ph.D., and...
Dec 07, 2022 08:00 am ET
Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that it will participate in the MedInvest Oncology Investor...
Nov 28, 2022 08:00 am ET
Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that it will participate in the RHK Capital Disruptive Growth...
Nov 14, 2022 04:05 pm ET
Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced plans for a Phase 1/2a trial of narazaciclib...
Nov 07, 2022 04:05 pm ET
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter Financial Results on November 14, 2022
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its third...
Sep 22, 2022 08:00 am ET
Onconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in-person in...
Sep 12, 2022 08:00 am ET
Onconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced updated data from an investigator-sponsored Phase...
Sep 01, 2022 08:00 am ET
Onconova Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating virtually in...
Aug 11, 2022 04:05 pm ET
Onconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended June...
Aug 04, 2022 04:05 pm ET
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its second...
Jun 13, 2022 08:00 am ET
Onconova Therapeutics Announces Key Management Promotions
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Mark Guerin was appointed Chief Operating Officer in addition...
May 26, 2022 05:10 pm ET
Onconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory and Improved Safety Profile in Preclinical Models
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of an abstract at the American Society of Clinical...
May 11, 2022 04:05 pm ET
Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended March...
May 04, 2022 04:05 pm ET
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter Financial Results on May 11, 2022
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its first...
Apr 27, 2022 10:16 am ET
Onconova Therapeutics Announces Acceptance of Abstract for Publication at the ASCO Annual Meeting
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the acceptance of an abstract for publication at the American...
Mar 23, 2022 08:00 am ET
Onconova Therapeutics to Present at the Next Generation Kinase Inhibitors Summit
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Adar Makovski Silverstein, Ph.D., Director of Corporate...
Mar 17, 2022 04:05 pm ET
Onconova Therapeutics Reports Full Year 2021 Financial Results and Provides Business Update
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the twelve months ended...
Mar 10, 2022 04:05 pm ET
Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2021 Financial Results on March 17, 2022
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its fourth quarter and full...
Feb 02, 2022 08:00 am ET
Onconova Therapeutics to Present at the Guggenheim Oncology Conference
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the Guggenheim Oncology...
Jan 04, 2022 08:00 am ET
Onconova Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the H.C. Wainwright...
Dec 13, 2021 08:00 am ET
Onconova Therapeutics Appoints Adar Makovski Silverstein, Ph.D., as Director, Corporate Development
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Dr. Adar Makovski Silverstein has joined Onconova as...
Dec 02, 2021 08:00 am ET
Onconova Therapeutics Announces the Presentation of Preliminary Clinical Data Providing Evidence of Rigosertib’s Activity in RDEB-associated Squamous Cell Carcinoma
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that early preliminary data from an investigator-initiated Phase 2...
Nov 22, 2021 08:00 am ET
Onconova Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the Piper Sandler 33rd...
Nov 11, 2021 04:01 pm ET
Onconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended...
Nov 04, 2021 08:00 am ET
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2021 Financial Results on November 11, 2021
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its third quarter 2021...
Sep 29, 2021 08:00 am ET
Onconova Therapeutics to Attend the Sachs 21st Annual Biotech in Europe Forum (BEF)
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will be attending...
Sep 28, 2021 04:05 pm ET
Onconova Therapeutics, Inc. Announces Closing of $21 Million Public Offering of Common Stock
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the closing of its previously announced underwritten...
Sep 24, 2021 08:00 am ET
Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the pricing of an underwritten public offering of 5,000,000 shares of its...
Sep 23, 2021 04:01 pm ET
Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it intends to offer and sell shares of its common stock in an...
Sep 22, 2021 09:31 am ET
Thinking about buying stock in Onconova Therapeutics, Spire Global, Exela Technologies, Matinas BioPharma, or Teck Resources?
NEW YORK, Sept. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONTX, SPIR, XELA, MTNB, and TECK.
Sep 22, 2021 08:00 am ET
Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preliminary safety and efficacy data from an...
Sep 20, 2021 08:00 am ET
Onconova Therapeutics Announces Upcoming Presentation at the 3rd Annual RAS Targeted Drug Development Summit
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced an upcoming presentation at the 3rd Annual RAS Targeted Drug...
Sep 09, 2021 08:00 am ET
Onconova Therapeutics Announces Participation at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the H.C. Wainwright 23rd...
Aug 12, 2021 04:05 pm ET
Onconova Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended June 30,...
Aug 05, 2021 08:00 am ET
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2021 Financial Results on August 12, 2021
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its second...
Jun 28, 2021 08:00 am ET
Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced an update on the investigator-initiated Phase 1/2a...
Jun 22, 2021 08:00 am ET
Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that on June 17, 2021 it received a letter from The Nasdaq Stock Market...
Jun 17, 2021 08:00 am ET
Onconova Therapeutics Announces the Peer-Reviewed Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Rigosertib Combined with Immune Checkpoint Blockade
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of a preclinical study in the journal...
Jun 10, 2021 08:30 am ET
Thinking about buying stock in Irving Resources, Soligenix, Exela Technologies, Soleno Therapeutics, or Onconova Therapeutics?
NEW YORK, June 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IRV, SNGX, XELA, SLNO, and ONTX.
Jun 10, 2021 08:00 am ET
Onconova Therapeutics Announces Participation in A.G.P.’s Upcoming Virtual Summer Healthcare Symposium
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will...
Jun 03, 2021 08:00 am ET
Onconova Therapeutics Announces Upcoming Presentation at 2021 BIO Digital
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova has been selected to present at 2021...
Jun 01, 2021 08:00 am ET
Onconova Therapeutics Announces the Appointment of Mark Gelder, M.D., as Chief Medical Officer
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Mark Gelder, M.D. will be joining Onconova as...
May 21, 2021 08:00 am ET
Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first patient has been dosed in the U.S. Phase 1 clinical...
May 20, 2021 08:31 am ET
Onconova Therapeutics Announces Reverse Stock Split and Decrease in Authorized Shares
Onconova Therapeutics, Inc. (Nasdaq: ONTX) (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced a one-for-fifteen reverse stock...
May 17, 2021 04:05 pm ET
Onconova Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended March...
May 10, 2021 08:00 am ET
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2021 Financial Results on May 17, 2021
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its first quarter 2021...
Apr 22, 2021 08:00 am ET
Onconova Announces First Patient Dosed in Investigator-Initiated Phase 2 Study of Rigosertib in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced today that the first patient has been dosed in an investigator-initiated...
Apr 01, 2021 08:00 am ET
Onconova Therapeutics Announces Enrollment in Second Cohort of Phase 1 Study with ON 123300 in China
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announces that its corporate partner HanX Biopharmaceuticals has enrolled three...
Mar 29, 2021 08:00 am ET
Onconova to Present at the Spring 2021 Oncology Investor Conference
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President and Chief...
Mar 11, 2021 04:05 pm ET
Onconova Therapeutics Reports Full Year 2020 Financial Results, Provides Business Update
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for patients with cancer, announces financial results for the twelve months ended December 31,...
Mar 04, 2021 04:15 pm ET
Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will release its year-end 2020 financial results...
Mar 01, 2021 08:00 am ET
Onconova Therapeutics to Participate in Three Investment Conferences During the Month of March
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President and Chief Executive Officer,...
Feb 24, 2021 08:00 am ET
Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announces receipt of notification from Nasdaq that the Company has regained...
Feb 16, 2021 04:03 pm ET
Onconova Therapeutics, Inc. Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment Option
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the closing of its previously-announced underwritten public offering. A total...
Feb 16, 2021 08:00 am ET
Onconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will present a virtual...
Feb 10, 2021 10:49 pm ET
Onconova Therapeutics, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the pricing of an underwritten public offering of 25,000,000 shares of its...
Feb 10, 2021 04:01 pm ET
Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it intends to offer and sell shares of its common stock in an...
Jan 14, 2021 08:00 am ET
Onconova Therapeutics, Inc. to Present at NobleCon17 Virtual Event
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, MD, President & CEO, will present a Company...
Jan 07, 2021 09:40 am ET
Onconova Therapeutics, Inc. Announces $8.7 Million Public Offering
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it has entered into a definitive purchase agreement with certain...
Jan 06, 2021 09:55 am ET
Thinking about buying stock in Sundial Growers, BioNano Genomics, Zomedica, Jaguar Health, or Onconova Therapeutics?
NEW YORK, Jan. 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, BNGO, ZOM, JAGX, and ONTX.
Dec 23, 2020 09:55 am ET
Thinking about buying stock in Onconova Therapeutics, Jaguar Health, Acasti Pharma, Zomedica, or Riot Blockchain?
NEW YORK, Dec. 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONTX, JAGX, ACST, ZOM, and RIOT.
Dec 21, 2020 08:00 am ET
Onconova Therapeutics Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced receipt of U.S. Food and Drug Administration (FDA) permission for a Phase 1 study to...
Dec 02, 2020 09:50 am ET
Thinking about buying stock in Sundial Growers, Zomedica, Advanced Micro Devices, Jaguar Health, or Onconova Therapeutics?
NEW YORK, Dec. 2, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, ZOM, AMD, JAGX, and ONTX.
Dec 01, 2020 09:35 am ET
Thinking about buying stock in Jaguar Health, Zomedica, Sundial Growers, Onconova Therapeutics, or Transocean?
NEW YORK, Dec. 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, ZOM, SNDL, ONTX, and RIG.
Nov 23, 2020 08:00 am ET
Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the filing of an Investigational New Drug application (IND) with the U.S. Food and Drug...
Nov 12, 2020 04:05 pm ET
Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today reported financial results for the quarter ended September 30, 2020 and provided a business update....
Nov 05, 2020 08:00 am ET
Onconova Therapeutics to Provide Corporate Update and Third Quarter 2020 Financial Results on November 12, 2020
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company intends to release its third quarter financial results on Thursday,...
Oct 13, 2020 08:00 am ET
Onconova Therapeutics to Present Update During the 2020 BIO Investor Forum Digital Event
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a...
Sep 21, 2020 08:00 am ET
Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals
Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the initiation of a Phase 1 clinical trial in China for ON 123300 by its partner, HanX...
Sep 09, 2020 08:00 am ET
Onconova Therapeutics Announces Participation at Upcoming Virtual Events
Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company plans to participate in several upcoming events: Marcus Evans Healthcare...
Aug 31, 2020 08:00 am ET
Onconova Therapeutics Announces Election of James J. Marino, JD, MBA as Chairman of the Board of Directors
Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the election of James J. Marino, JD, MBA as Chairman of the Board of Directors. Mr. Marino...
Aug 24, 2020 07:30 am ET
Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial
Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that INSPIRE, the company’s pivotal Phase 3 study assessing the efficacy and safety of IV...
Aug 12, 2020 04:05 pm ET
Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today reported financial results...
Aug 07, 2020 08:00 am ET
Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that the Company...
Aug 04, 2020 08:00 am ET
Onconova Therapeutics Announces Compliance with Nasdaq Bid Price Requirement
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that on August 3,...
Jul 29, 2020 01:30 pm ET
Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that the required...
Jul 27, 2020 09:31 am ET
Thinking about buying stock in Riot Blockchain, Onconova Therapeutics, Capricor Therapeutics, Genocea Biosciences, or eMagin Corp?
NEW YORK, July 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RIOT, ONTX, CAPR, GNCA, and EMAN.
Jul 27, 2020 08:00 am ET
Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it has...
Jul 23, 2020 09:31 am ET
Thinking about buying stock in Genocea Biosciences, Sunworks Inc, Onconova Therapeutics, United Airlines, or General Electric?
NEW YORK, July 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GNCA, SUNW, ONTX, UAL, and GE.
Jul 23, 2020 08:00 am ET
Onconova Therapeutics Announces Publication of Preclinical Data Supporting Rigosertib’s Mechanism of Action as a Targeted Anticancer Therapy
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the publication...
Jul 21, 2020 09:31 am ET
Thinking about buying stock in Caesars Entertainment, Moleculin Biotech, Onconova Therapeutics, Capricor Therapeutics, or Diffusion Pharmaceuticals?
NEW YORK, July 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CZR, MBRX, ONTX, CAPR, and DFFN.
Jul 07, 2020 08:00 am ET
Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the e-publication...
Jun 23, 2020 08:00 am ET
Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced its participation...
Jun 22, 2020 08:00 am ET
Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS) today announced an...
Jun 12, 2020 08:00 am ET
Onconova Therapeutics Announces Presentation at the 25th Congress of the European Hematology Association (EHA)
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced updated aggregated...
Jun 11, 2020 10:30 am ET
Thinking about buying stock in Onconova Therapeutics, Royal Caribbean Cruises, Delta Air Lines, Bank of America, or Occidental Petroleum Corp?
NEW YORK, June 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONTX, RCL, DAL, BAC, and OXY.
Jun 08, 2020 08:00 am ET
Onconova Therapeutics Announces Presentation at BIO Digital 2020
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that Avi Oler,...
May 22, 2020 09:31 am ET
Thinking about buying stock in Navidea Biopharmaceuticals, Aurora Cannabis, Under Armour, Onconova Therapeutics, or BJs Wholesale Club?
NEW YORK, May 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NAVB, ACB, UA, ONTX, and BJ.
May 15, 2020 10:45 am ET
Thinking about buying stock in Sorrento Therapeutics, Cassava Sciences, Diffusion Pharma, Onconova Therapeutics, or Bridgeline Digital?
NEW YORK, May 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, SAVA, DFFN, ONTX, and BLIN.
May 14, 2020 04:05 pm ET
Onconova Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today reported financial results...
May 11, 2020 08:00 am ET
Onconova Therapeutics Announces Virtual Format for 2020 Annual Meeting of Stockholders
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that, as disclosed...
May 07, 2020 08:00 am ET
Onconova Therapeutics to Provide Corporate Update and First Quarter 2020 Earnings on May 14, 2020
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that the Company...
Apr 27, 2020 08:00 am ET
Onconova Therapeutics Strengthens Board of Directors with Nomination of Life Sciences Industry Veteran
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the nomination of...
Mar 24, 2020 04:05 pm ET
Onconova Therapeutics Announces Completion of Enrollment of Phase 3 INSPIRE Trial, Provides a Corporate Update, and Reports 2019 Financial Results
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today reported financial results...
Mar 18, 2020 08:00 am ET
Onconova Therapeutics to Provide Corporate Update and Full Year 2019 Financial Results
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), today announced that the Company will...
Feb 18, 2020 08:00 am ET
Onconova Therapeutics Announces Participation in Two Upcoming International Conferences
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that the Company will be...
Feb 10, 2020 08:00 am ET
Onconova Therapeutics to Present Update at Noble Capital Markets’ Sixteenth Annual Investor Conference in Hollywood, FL
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that Dr. Steven M. Fruchtman,...
Feb 04, 2020 08:00 am ET
Onconova Therapeutics to Present Update at the 2020 BIO CEO & Investor Conference in New York City
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that Dr. Steven M. Fruchtman,...
Jan 23, 2020 08:30 am ET
Onconova Therapeutics Regains Rigosertib Rights in Greater China
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it has regained the...
Jan 03, 2020 01:27 pm ET
Onconova Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced...
Dec 31, 2019 11:30 am ET
Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced...
Dec 19, 2019 01:44 pm ET
Onconova Therapeutics, Inc. Announces Closing Of $5.0 Million Registered Direct Offering Priced At-The-Market
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced...
Dec 18, 2019 09:05 am ET
Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced...
Dec 18, 2019 09:00 am ET
Onconova Therapeutics Announces Exclusive License Agreement with Specialised Therapeutics for Rigosertib in Australia and New Zealand
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), today announced it has entered into a...
Dec 17, 2019 07:30 am ET
Onconova Therapeutics and Pint Pharma Announce Brazilian Health Authority Approval for Initiating INSPIRE Trial with Intravenous Rigosertib in Higher-Risk Myelodysplastic Syndromes in Brazil
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), and Pint Pharma, a European-based...
Dec 10, 2019 03:07 pm ET
Onconova Therapeutics, Inc. Announces Closing of $5.0 Million Registered Direct Offering Priced At-the-Market
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced...
Dec 09, 2019 09:00 am ET
Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Ri
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced data presented...
Dec 09, 2019 08:00 am ET
Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it has...
Dec 06, 2019 07:30 am ET
Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), and Inceptua Medicines Access (a...
Nov 25, 2019 09:26 am ET
Onconova Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), today announced the closing of its...
Nov 21, 2019 11:23 am ET
Onconova Therapeutics, Inc. Announces $11.0 Million Public Offering
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), today announced that it has priced a...
Nov 21, 2019 10:16 am ET
Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics for Rigosertib in Canada
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), today announced they have entered into a...
Nov 07, 2019 07:30 am ET
Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), today announced that five abstracts relating to the...
Oct 24, 2019 07:30 am ET
Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), announced that the Company believes it...
Sep 23, 2019 08:52 am ET
Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common Stock
Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), today announced that it has entered into securities...
Sep 18, 2019 10:05 am ET
Onconova Therapeutics Announces Termination of Proposed Public Offering
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS) today announced that it has decided to terminate the...
Sep 16, 2019 07:30 am ET
Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), will present at the RAS-Targeted Drug Discovery Summit...
Aug 14, 2019 07:30 am ET
Onconova Therapeutics, Inc. Reports Business Highlights and Second Quarter 2019 Financial Results
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), today provided a corporate update and reported...
Aug 12, 2019 07:30 am ET
Onconova Therapeutics and Mission Bio Partner to Advance Precision Oncology Clinical Trials Employing Single-Cell Genomics
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), and Mission Bio, the pioneer in targeted single-cell...
Aug 07, 2019 07:30 am ET
Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2019 Financial Results
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), today announced that the Company will...
Jun 10, 2019 07:30 am ET
Onconova Therapeutics Announces Presentations at the 24th Congress of the European Hematology Association
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced two presentations...
May 28, 2019 07:30 am ET
Onconova Therapeutics Announces Presentations at Three Upcoming Conferences
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it will be...
May 14, 2019 07:30 am ET
Onconova Therapeutics, Inc. Reports Business Highlights and First Quarter 2019 Financial Results
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS), today...
May 13, 2019 07:30 am ET
Onconova Therapeutics Announces License Agreement with HanX Biopharmaceuticals to Develop and Commercialize Rigosertib in Greater China
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it has entered...
May 07, 2019 07:30 am ET
Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2019 Financial Results
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today...
May 06, 2019 07:30 am ET
Onconova Therapeutics Announces Presentations at the 15th International Symposium on Myelodysplastic Syndromes (MDS 2019) in Copenhagen, Denmark
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today...
Apr 02, 2019 07:30 am ET
Onconova Therapeutics to Present Update at the 2019 HCW Global Life Sciences Conference in London, April 7-9
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that the Company...
Mar 26, 2019 07:30 am ET
Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2018 Financial Results
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today...
Mar 25, 2019 07:30 am ET
Onconova Achieves Over 75 Percent of Planned Enrollment in Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes
Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer today announced that it has surpassed the 75 percent enrollment milestone in...
Mar 19, 2019 07:30 am ET
Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2018 Financial Results
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced that the Company will...
Mar 12, 2019 07:30 am ET
Onconova Therapeutics, Inc. to Participate at the 31st Annual ROTH Conference March 17-19, 2019 in Orange County, CA
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced that the Company will...
Feb 04, 2019 08:00 am ET
Onconova Therapeutics, Inc. to Present Corporate Update at the BIO CEO & Investor Conference in New York City
Onconova Therapeutics, Inc. (NASDAQ:ONTX), Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes...
Jan 31, 2019 07:30 am ET
Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City
Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced it will host a KOL...
Jan 22, 2019 07:30 am ET
Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Dr. Steven M. Fruchtman, President & CEO, will present a...
Jan 15, 2019 05:15 pm ET
Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced the appointment of...
Jan 02, 2019 07:30 am ET
Onconova Submits Special Protocol Assessment (SPA) to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine (Vidaza®) for First-Line Myelodysplastic Syndromes (MDS)
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on MDS, today announced that it has submitted a Special Protocol...
Dec 31, 2018 07:30 am ET
Onconova to Meet Investors and Potential Partners at China Focus and the 37th Annual J.P. Morgan Healthcare Conferences in San Francisco
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that Management will...
Dec 10, 2018 07:30 am ET
Onconova Welcomes Avi Oler, JD, MBA, as Vice President, Corporate Development and General Counsel
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that Mr. Abraham...
Dec 03, 2018 07:30 am ET
Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting
MDS patient population NEWTOWN, Pa., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, announces...
Nov 13, 2018 07:00 am ET
Onconova Therapeutics Announces Business Highlights and Financial Results for Third Quarter 2018
Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company focused on developing rigosertib, a novel small molecule drug candidate to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided a...
Nov 07, 2018 08:30 am ET
Onconova Welcomes Richard (Ric) Woodman, M.D., as Chief Medical Officer (CMO)
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced the appointment of...
Nov 05, 2018 08:30 am ET
Onconova Announces Four Presentations from Rigosertib Clinical Trials in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting & Exposition
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that four abstracts relating to the Company's lead product...
Nov 01, 2018 08:30 am ET
Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2018 Financial Results
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced that the Company will...
Oct 29, 2018 08:30 am ET
Onconova Therapeutics to Meet with Potential Investors and Business Development Partners at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that Dr. Ramesh...
Oct 17, 2018 08:30 am ET
Onconova Therapeutics Announces Issuance of a New U.S. Patent for Rigosertib
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced that the United...
Oct 10, 2018 08:30 am ET
Onconova Therapeutics to Present Update at the 2018 BIO Investor Forum in San Francisco
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that the Company...
Sep 25, 2018 09:16 am ET
Onconova Therapeutics Announces Reverse Stock Split
Onconova Therapeutics, Inc. (Nasdaq: ONTX) (“Onconova” or “the Company”), a Phase 3 stage biopharmaceutical company focused on developing rigosertib, a novel small molecule drug candidate to treat cancer, with a primary focus on Myelodysplastic...
Aug 28, 2018 08:30 am ET
Onconova Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference in New York City
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that the Company...
Aug 21, 2018 08:30 am ET
Onconova Therapeutics Announces Plan for Expanding Rigosertib Clinical Trials for Patients with Myelodysplastic Syndromes (MDS) to South America with Pint Pharma
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that its commercial...
Aug 14, 2018 08:00 am ET
Onconova Therapeutics Reports Business Highlights and Financial Results for Second Quarter 2018
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on developing rigosertib, a novel small molecule drug candidate to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided a...
Aug 07, 2018 08:00 am ET
Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2018 Financial Results
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced that the Company will...
Jun 21, 2018 08:00 am ET
Onconova Therapeutics Announces Promotion for Steven M. Fruchtman, M.D.
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced the promotion of Dr....
Jun 07, 2018 08:30 am ET
Onconova Therapeutics Announces Presentation at the 23rd Congress of the European Hematology Association
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced a presentation at...
May 15, 2018 08:30 am ET
Onconova Therapeutics, Inc. Reports Business Highlights and Financial Results for First Quarter 2018
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided...
May 09, 2018 08:30 am ET
Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2018 Financial Results
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced that the Company will...
May 03, 2018 08:00 am ET
Onconova Therapeutics to Present at the Disruptive Growth and Healthcare Conference on May 8th, 2018
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), announced that the Company will...
May 01, 2018 06:33 pm ET
Onconova Therapeutics Announces Closing of $28.75 Million Upsized Underwritten Public Offering
NEWTOWN, Pa., May 01, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or “we”), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic...
Apr 27, 2018 06:00 am ET
Onconova Therapeutics Announces Pricing of $25.0 Million Upsized Underwritten Public Offering
NEWTOWN, Pa., April 27, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or “we”), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic...
Apr 19, 2018 08:30 am ET
Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting
NEWTOWN, Pa., April 19, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, announced an advance in pre-clinical development and the presentation of new...
Mar 26, 2018 08:30 am ET
Onconova Presents Promising Data from Phase 2 Expansion Study of Oral Rigosertib and Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Failure Disease
NEWTOWN, Pa., March 26, 2018 (GLOBE NEWSWIRE) --  Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, presented promising new clinical safety data from the expansion phase...
Mar 15, 2018 08:00 am ET
Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American Association for Cancer Research Annual Meeting 2018
NEWTOWN, Pa., March 15, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), will present new...
Mar 08, 2018 07:00 am ET
Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2017 Financial Results
NEWTOWN, Pa., March 08, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes...
Mar 06, 2018 08:30 am ET
Onconova Therapeutics to Present at the 30th Annual Roth Conference in March
NEWTOWN, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes...
Mar 05, 2018 08:00 am ET
Onconova Therapeutics Announces License Agreement with Pint Pharma to Commercialize Rigosertib for Treatment of Myelodysplastic Syndromes in Latin America
• Pint Pharma to Make Upfront Investment in Onconova• Onconova also Eligible to Receive up to $42.75 Million in Regulatory and Sales Milestones
Mar 04, 2018 10:00 am ET
Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at American Association for Cancer Research (AACR) Epigenetics Conference
NEWTOWN, Pa., March 04, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), announced the...
Mar 01, 2018 12:00 pm ET
Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2017 Financial Results
Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Thursday, March 8, 2018

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.